Arthur Krieg

Arthur Krieg

Company: Checkmate Pharmaceuticals

Job title: Chief Scientific Officer


Arthur M. Krieg, MD has worked in the oligonucleotide field since the 1980s.  Most recently he founded Checkmate Pharmaceuticals to develop novel oligonucleotides for cancer immunotherapy, where he currently serves as CSO.  Prior to that role Art was CSO at Sarepta until July 2014; co-founder and CEO at RaNA Therapeutics from 2011 to 2013; CSO of Pfizer’s Oligonucleotide Therapeutics Unit from 2008 to 2011; and co-founder, CSO of Coley Pharmaceutical Group from 1997 until its acquisition and incorporation into Pfizer in 2008.  Art discovered the immune stimulatory CpG DNA motif in 1994, which led to a new approach to immunotherapy and vaccine adjuvants.  Based on this technology he co-founded Coley Pharmaceutical Group in 1997, discovering and taking 4 novel oligonucleotides into clinical development.  Art co-founded the first antisense journal, Nucleic Acid Therapeutics, which he edited for 16 years, and the Oligonucleotide Therapeutics Society, for which he recently served as President.  He is a Professor in the University of Massachusetts RNA Therapeutics Institute and he serves on the scientific advisory boards of several companies developing oligonucleotide therapeutics.   

Art graduated from Haverford College in 1979, received his MD from Washington University in 1983, and completed a residency in Internal Medicine at the University of Minnesota in 1986.  He was a Staff Fellow at the NIH in the Arthritis Institute from 1986 to 1991, when he joined the University of Iowa, becoming Professor of Internal Medicine in the Division of Rheumatology. He has had 19 years of patient care experience, although his focus has always been on basic research and teaching.  Art left academia and joined Coley full-time in 2001.  He has published more than 250 scientific papers, and is an inventor on >50 issued US patents covering oligonucleotide technologies. 


Live Q&A 3:10 pm

Read more

day: Online Conference

Induction of Durable Tumor Regression in Advanced PD-1 refractory Melanoma with Intratumoral injection of CMP-001, a CpG-A oligodeoxynucleotide in a Virus-like Particle 2:30 pm

• Tumor-associated plasmacytoid dendritic cells (pDC) mediate tumor tolerance vs. Immunity • CMP-001 activates pDC into the most powerful IFN-secreting cells known • Intratumoral injection of CMP-001 can induce a systemic T cell response that eradicates visceral metastasesRead more

day: Online Conference

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.